



GAU-1645.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Small et al.

Examiner: Unassigned

Serial No.: 09/636,259

Group Art Unit: 1645

Filed: August 10, 2000

Docket: 13092

For: Alpha-2A-adrenergic receptor polymorphisms

Dated: April 3, 2001

RECEIVED
APR 10 2001
TECH CENTER 1600/2900
[Handwritten signatures]

Kalow & Springut LLP
488 Madison Avenue, 19th Fl
New York, NY 10022

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. 1.97(b), the attorneys for the Applicants hereby bring to the attention of the Patent and Trademark Office the following documents related to the field of the invention of the application identified above:

I. U.S. PATENT DOCUMENTS

<u>Patent No.</u>	<u>Date Issued</u>	<u>Title</u>
5,648,482 to Meyer	Jul. 15, 1997	Primers Targeted to CYP2D6 Gene for Detecting Poor Metabolizers of Drugs
5,846,710 to Bajaj	Dec. 8, 1998	Method for the Detection of Genetic Diseases and Gene Sequence Variations by Single Nucleotide Primer Extension

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby declare that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231

4/3/01
Date

J. Colwell
Name

<u>Patent No.</u>	<u>Date Issued</u>	<u>Title</u>
5,856,092 to Dale et al.	Jan. 5, 1999	Detection of a Nucleic Acid Sequence or a Change Therein
5,888,819 to Goelet et al.	Mar. 30, 1999	Method for Determining Nucleotide Identity Through Primer Extension
5,981,174 to Wolf et al.	Nov. 9, 1999	Genetic Assay
6,004,744 to Goelet et al.	Dec. 21, 1999	Method for Determining Nucleotide Identity Through Extension of Immobilized Primer
6,013,431 to Soderlund et al.	Jan. 11, 2000	Method for Determining Specific Nucleotide Variations by Primer Extension in the Presence of Mixture of Labeled Nucleotides and Terminators
6,156,503 to Drazen et al.	Dec. 5, 2000	Diagnosing Asthma Patients Predisposed to Adverse β -Agonist Reactions

II. NON PATENT PUBLICATIONS

Limbird, L.E. (1988) *FASEB J* **2**, 2686-2695.

Luttrell, L.M., van Biesen, T., Hawes, B.E., Della Rocca, G.J., Luttrell, D.K., and Lefkowitz, R.J. (1998) in *Catecholamines: Bridging Basic Science with Clinical Medicine* (Goldstein, D.S., Eisenhofer, G., and McCarty, R., eds) pp. 466-470, Academic Press.

Ruffolo, R.R., Jr., Nichols, A.J., Stadel, J.M., and Hieble, J.P. (1993) *Annu Rev Pharmacol Toxicol* **32**, 243-279.

Hein, L., Altman, J.D., and Kobilka, B.K. (1999) *Nature* **402**, 181-184.

Altman, J.D., Trendelenburg, A.U., MacMillan, L., Bernstein, D., Limbird, L., Starke, K., Kobilka, B.K., and Hein, L. (1999) *Mol. Pharmacol.* **56**, 154-161.

Lakhlani, P.P., MacMillan, L.B., Guo, T.Z., McCool, B.A., Lovinger, D.M., Maze, M., and Limbird, L.E. (1997) *Proc Natl Acad Sci USA* **94**, 9950-9955.

Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. (1983) *Drugs* **26**, 212-229.

Dao, T.T., Kailasam, M.T., Parmer, R.J., Le, H.V., Le Verge, R., Kennedy, B.P., Ziegler, G., Insel, P.A., Wright, F.A., and O'Connor, D.T. (1998) *J Hypertens* **16**, 779-792.

Goldstein, D.S., Grossman, E., Listwak, S., and Folio, C.J. (1991) *Hypertension* **18**, III40-III48.

Lockette, W., Ghosh, S., Farrow, S., MacKenzie, S., Baker, S., Miles, P., Schork, A., and Cadaret, L. (1995) *Am J Hypertens* **8**, 390-394.

Svetkey, L.P., Timmons, P.Z., Emovon, O., Anderson, N.B., Preis, L., and Chen, Y.-T. (1996) *Hypertension* **27**, 1210-1215.

Liggett, S.B. (1998) *Clin and Exp.Allergy* **28**, 77-79.

Guyer, C.A., Horstman, D.A., Wilson, A.L., Clark, J.D., Cragoe, E.J.Jr., and Limbird, L.E. (1990) *J Biol Chem* **265**, 17307-17317.

Rutkowski, M.P., Klanke, C.A., Su, Y.R., Reif, M., and Menon, A.G. (1998) *Hypertension* **31**, 1230-1234.

Eason, M.G. and Liggett, S.B. (1992) *J.Biol.Chem.* **267**, 25473-25479.

Jewell-Motz, E.A. and Liggett, S.B. (1996) *J.Biol.Chem.* **271**, 18082-18087.

de chasseval, R. and de Villartay, J.-P. (1991) *Nucleic Acids Research* **20**, 245-250.

Eason, M.G., Moreira, S.P., and Liggett, S.B. (1995) *J.Biol.Chem.* **270**, 4681-4688.

Jewell-Motz, E.A., Donnelly, E.T., Eason, M.G., and Liggett, S.B. (1998) *Biochem* **37**, 15720-15725.

Schwinn, D.A., Page, S.O., Middleton, J.P., Lorenz, W., Liggett, S.B., Yamamoto, K., Caron, M.G., Lefkowitz, R.J., and Cotecchia, S. (1991) *Mol.Pharmacol.* **40**, 619-626.

Martin, T.F.J. (1983) *J Biol Chem* **258**, 14816-14822.

Eason, M.G., Jacinto, M.T., Theiss, C.T., and Liggett, S.B. (1994) *Proc.Natl.Acad.Sci., USA* **91**, 11178-11182.

Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., and Klenk, D.C. (1985) *Anal.Biochem.* **150**, 76-85.

Eason, M.G. and Liggett, S.B. (1996) *J.Biol.Chem.* **271**, 12826-12832.

Exton, J.H. (1996) *Annu Rev Pharmacol Toxicol* **36**, 481-509.

MacMillan, L.B., Lakhani, P., Lovinger, D., and Limbird, L.E. (1998) *Recent Prog Horm Res* **53**, 25-42.

Makaritsis, K.P., Johns, C., Gavras, I., Altman, J.D., Handy, D.E., Bresnahan, M.R., and Gavras, H. (1999) *Hypertension* **34**, 403-407.

Spiegel, A.M. (1996) *Annu Rev Physiol* **58**, 143-170.

Kotanko, P., Binder, A., Tasker, J., DeFreitas, P., Kamdar, S., Clark, A.J., Skrabal, F., and Caulfield, M. (1997) *Hypertension* **30**, 773-776.

Liggett, S.B., Wagoner, L.E., Craft, L.L., Hornung, R.W., Hoit, B.D., McIntosh, T.C., and Walsh, R.A. (1998) *J Clin Invest* **102**, 1534-1539.

Tan, S., Hall, I.P., Dewar, J., Dow, E., and Lipworth, B. (1997) *Lancet* **350**, 995-999.

Green, S.A., Cole, G., Jacinto, M., Innis, M., and Liggett, S.B. (1993) *J Biol Chem* **268**, 23116-23121.

Shenker, A., Laue, L., Kosugi, S., Merendino, J.J., Minegishi, T., and Cutler, G.B. (1993) *Nature Lond* **365**, 652-654.

WEB PAGE

<http://www.adrenoceptor.com/alphaintro.htm> (visited April 2, 2001)

<http://www.tocris.com/adrenoceptor.htm> (visited March 12, 2001)

The items listed above are identified on Form PTO 1449 which is submitted with this statement. A copy of each of the items identified above is submitted with this statement.

The attorneys for the Applicant take no position on whether or not any item cited above and listed on Form PTO 1449 constitutes prior art against the subject application under any particular provision of Title 35 of the United States Code.


Applicant: Small et al.

Serial No.: 09/636,259

April 3, 2001

If a fee is deemed necessary, please charge any payment, or credit any overpayment, to deposit account no. 11-0171.

Respectfully submitted,



William D. Schmidt
Registration No. 39,492

Telephone: (212) 813-1600

Facsimile: (212) 813-9600

T:\PATENTS\Applications\13092\InformationDisclosureStatement.doc